Welcome to our dedicated page for Rani Therapeutics Holdings news (Ticker: RANI), a resource for investors and traders seeking the latest updates and insights on Rani Therapeutics Holdings stock.
Rani Therapeutics Holdings, Inc. (Nasdaq: RANI) is a trailblazing clinical-stage biotherapeutics company focused on revolutionizing drug delivery through its proprietary platform technology. The company's main innovation, the RaniPill capsule, aims to transform the administration of biologics by making it possible to deliver these typically injectable drugs orally. This groundbreaking approach offers a convenient alternative to patients who frequently endure painful subcutaneous or intravenous injections.
The RaniPill technology has been designed to handle various drug substances, including antibodies, proteins, peptides, and oligonucleotides. Among its key advancements, Rani Therapeutics has introduced the RaniPill HC, a high-capacity capsule that can deliver drug payloads up to 200 microliters in liquid form with high bioavailability. This novel capsule has shown promising results in preclinical studies, demonstrating high reliability and the potential to mimic parenteral drug administration.
Rani Therapeutics has successfully conducted multiple preclinical and clinical trials to evaluate the safety, tolerability, and bioavailability of the RaniPill technology. Significant progress includes the development of two RaniPill capsules: RaniPill GO and RaniPill HC. These trials have validated the platform's ability to convert injectable biologics into oral formats, paving the way for further clinical advancements.
Recently, Rani Therapeutics reported its preliminary consolidated financial results for the third quarter ending September 30, 2023. The company is strategically prioritizing its RT-102 and RT-111 programs while advancing the RaniPill HC towards Phase 1 clinical readiness by the second half of 2024. The company expects to initiate the Phase 2 study of RT-102 in 2023 and aims to achieve key milestones that extend its operational cash runway into 2025.
Looking ahead, Rani Therapeutics continues to focus on expanding its manufacturing capabilities to support scaling and potential partnering opportunities. The company remains committed to its vision of making oral biologics a reality across various therapeutic indications, driving significant value for patients, healthcare providers, and shareholders.
Rani Therapeutics reported its Q3 2022 financial results and key corporate updates on Nov. 10, 2022. The highlights include positive topline results from the Phase 1 study of RT-102, a proprietary PTH formulation, and the initiation of preclinical development for RT-111, a biosimilar targeting autoimmune conditions. Financially, Rani ended Q3 with cash reserves of $98.7 million. Although R&D expenses decreased to $9.1 million, the net loss reduced to $16.2 million from $28.7 million year-over-year. Upcoming milestones involve additional data from RT-102 and new Phase 1 studies in 2023.
Rani Therapeutics, a clinical stage biotherapeutics company, will present at the Stifel Healthcare Conference on November 15-16, 2022. CEO Talat Imran is scheduled to speak on November 16 at 9:45 AM EST. The company focuses on oral delivery of biologics through its innovative RaniPill capsule technology, aimed at replacing injections with oral dosing. Interested parties can access live webcasts from the Investor Relations section of their website, with replays available for 90 days post-presentation.
Rani Therapeutics announced the preclinical development of RT-111, an oral ustekinumab biosimilar targeting psoriatic arthritis, ulcerative colitis, Crohn's disease, and psoriasis. The product aims to simplify patient treatment by replacing injections with oral delivery.
Additionally, topline data for RT-102 is expected in Q4 2022, alongside the start of in vivo studies for the RaniPill HC. The company also plans to ramp up its pipeline with three new Phase 1 studies in 2023.
Rani Therapeutics Holdings (Nasdaq: RANI) announced its participation in the H.C. Wainwright Global Investment Conference, scheduled for September 12-14, 2022. CEO Talat Imran will deliver a presentation on September 12 at 8:30 AM EST. The conference will be accessible virtually and in-person, with a webcast available via the Investor Relations section of Rani's website. Rani Therapeutics focuses on innovative oral delivery systems for biologics, utilizing its patented RaniPill capsules to replace traditional injection methods.
Rani Therapeutics announced the termination of its previously announced underwritten public offering of Class A common stock, as management assessed the current market conditions as unfavorable. Consequently, no shares will be sold in this offering. The company asserted it has adequate capital to fund operations into mid-2024. The offering was to be conducted under an effective shelf registration statement. Forward-looking statements regarding cash reserves highlight potential risks and uncertainties affecting future results.
Rani Therapeutics Holdings has announced its intention to conduct an underwritten public offering of Class A common stock. The offering may include a 30-day option for underwriters to purchase up to 15% more shares. This action is contingent on market conditions and could affect the stock's performance. BofA Securities, Cantor, and UBS Investment Bank are leading the offering, which is being facilitated under a shelf registration statement effective as of August 10, 2022. The company emphasizes that no securities will be sold in jurisdictions where the offering would be unlawful.
Rani Therapeutics announced positive topline results from its Phase 1 trial of RT-102, a treatment for osteoporosis, demonstrating high oral bioavailability and successful drug delivery. The company completed a debt financing agreement of up to $45 million, ensuring operations are funded into mid-2024. Rani plans to initiate a third Phase 1 clinical trial and expects topline results from the repeat-dose portion of RT-102 by Q4 2022. As of June 30, 2022, cash and equivalents were $97.2 million, while R&D expenses rose significantly year-over-year to $9.5 million.
Rani Therapeutics announced positive topline results from its Phase 1 clinical study of RT-102, an oral capsule with human parathyroid hormone (PTH) analog for osteoporosis treatment. The study demonstrated that RT-102 was well-tolerated, with a 95% drug delivery success rate and a bioavailability of 300-400% greater than subcutaneous injections. The company aims to file an IND for Phase 2 trials by Q3 2023, building on the success of RT-101 and further validating the RaniPill platform.
Rani Therapeutics (RANI) reported its Q1 2022 financial results, highlighting the initiation of a Phase 1 trial for RT-102, aimed at treating osteoporosis. The company unveiled the RaniPill HC, which can deliver more than 20 mg of therapeutic payloads, enhancing its pipeline potential. Rani's cash position stood at $107.8 million, sufficient for operations through 2023. R&D expenses increased to $7.6 million, while general and administrative expenses rose to $6.2 million. The net loss for the quarter was $13.8 million, up from $5.6 million in Q1 2021.
SAN JOSE, Calif., May 3, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics, a clinical-stage biotherapeutics company, announced that CEO Talat Imran will present at two investment conferences in May. The Bank of America 2022 Healthcare Conference is scheduled for May 10 at 5:20 PM PT, while the H.C. Wainwright Annual Global Life Sciences Conference will take place on May 24 at 10:30 AM PT. Interested participants can access the live webcasts on Rani's Investor Relations page, with replays available for 90 days post-presentation.
FAQ
What is the current stock price of Rani Therapeutics Holdings (RANI)?
What is the market cap of Rani Therapeutics Holdings (RANI)?
What is Rani Therapeutics Holdings, Inc.?
What is the RaniPill capsule?
What drugs can the RaniPill capsule deliver?
What is the difference between RaniPill GO and RaniPill HC?
What recent achievements has Rani Therapeutics made?
What are Rani Therapeutics' future plans?
How have RaniPill capsules performed in clinical trials?
What are the benefits of the RaniPill technology?
How does Rani Therapeutics plan to scale its manufacturing?
Where can I find more information about Rani Therapeutics?
